(Reuters) -Medtech firm Heartflow was valued at $2.27 billion on Friday, with its shares surging 47.4% in the Nasdaq debut, ...

Bain Capital Specialty Finance delivered a strong Q2, reinforcing its value, dividend safety, and limited downside risk. Read ...

Heartflow (NASDAQ: HTFL) stock surges ~50% as the company focused on AI-driven tools for the diagnosis of heart diseases make ...

Heartflow, backed by private investment firm Bain Capital, said on Wednesday it was targeting a valuation of up to $1.46 ...

Bain Capital Specialty Finance Inc (NYSE:BCSF) is set to release its Q2 2025 earnings on Aug 6, 2025. The consensus estimate ...

On a per-share basis, the Boston-based company said it had profit of 37 cents. Earnings, adjusted for investment costs, were ...

Heartflow is advancing coronary care by transforming coronary artery disease into a screenable, diagnosable, and manageable ...

Pharma is looking for fewer, scaled providers at an enterprise level to reduce risk and provide a better-integrated service,' ...

Medical technology company Heartflow said on Friday it was targeting a valuation of up to $1.32 billion in its U.S. initial ...

Bain Capital and 11North Partners paid $395 million for a portfolio of 10 shopping centers in Florida and South Carolina, ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Bristol Myers Squibb (BMS) and Bain Capital have created an independent biopharmaceutical company to develop immunology ...